Biotest stands for high-quality and safe products as well as for efficient and reliable solutions. These are our characteristics that we intend to further develop. 
 
Coagulation disorders, disorders of the immune system, treatment of severe injuries – plasma proteins are used in very different medical settings. They serve prophylaxis or long-term therapy of chronic disease, and they are used in intensive care and emergency medicine.
When we speak of quality referring to plasma proteins, we mean safety, tolerability, and user friendliness. This goal being set, we continuously improve our products.
 
One example to facilitate application of our products is the development of subcutaneous injections. This enables patients to administer the drugs themselves, whereas intravenous injections may only be administered by medical doctors or specialised staff. With the drug Zutectra® we aim at launching a hepatitis immunoglobulin that features exactly this suitability.
 
One example to achieve the highest possible safety level is the fact that we have integrated additional steps of control and virus inactivation into the production process of plasma proteins; these steps are far more than the legally required procedures.

In all business areas, a close dialogue with the users is essential to us. Biotest is in regular contact with hospitals, laboratories, and research institutions – with a great number of our partners, we have already been co-operating for decades. That way, we are always well informed about the current state of developments in our specialty.